115例药物致肝脏药品不良反应分析

doi:10.19803/j.1672-8629.2022.02.19

摘要/Abstract

摘要： 目的了解药物致肝脏相关不良反应的发生情况及临床特点,为临床用药提供参考。方法采用回顾性分析方法,运用医院信息管理系统,收集西安市第一医院2016年1月1日至2019年12月31日药物致肝脏相关不良反应病例115例。对患者一般资料、生化指标、临床分型、损伤程度、涉及药品、不良反应发生时间、临床转归及治疗药物情况等进行统计分析。结果男性50例,女性65例,平均年龄（57.98±16.64）岁。药物导致肝脏不良反应多发生在服药后3个月内（74例,62.71%）,涉及肝脏不良反应药物排名前3位的是心血管系统药物（38例,32.20%）、中药（32例,27.12%）及内分泌系统药物（13例,11.02%）。结论女性更易发生药物性肝脏不良反应,最多见引发肝脏不良反应的药物为心血管系统药物。提示医疗机构应加强医务人员培训,提高医务人员对药物致肝脏相关不良反应的认识,做到积极预防,尽早识别,及时治疗。

关键词: 肝脏, 药品不良反应, 合理用药

Abstract: Objective To investigate the incidence and clinical characteristics of drug-induced liver injury and provide reference for medication. Methods The medical records of drug induced liver injury collected from the hospital information management system between January 1, 2016 and December 31, 2019 were retrospectively analyzed. The basic information, biochemical indexes, clinical classification, grades of injuries, drugs involved, onset time, outcomes and therapeutic drugs were recorded. Results Fifty males and sixty-five females with a mean age of (57.98±16.64) years were enrolled in this study. Drug induced liver injury mostly occurred within 3 months of medication (n=74, 62.71%). The top three drugs were cardiovascular agents (n=38, 32.20%), traditional Chinese medicine (n=32, 27.12%) and endocrine drugs (n=13, 11.02%). Conclusion This study has found that females are more vulnerable to liver injury, and that cardiovascular drugs are most likely to lead to liver injury. Medical institutions should strengthen medical staff's training, advance their understanding of drug induced liver injury, and ensure active prevention, early identification and quick treatment for patients.

Key words: liver, adverse drug reaction, rational drug use

中图分类号:

R994.11

吕娟, 郭未艳, 王园姬, 李亚美, 王颖丽, 段石顽. 115例药物致肝脏药品不良反应分析[J]. 中国药物警戒, 2022, 19(2): 200-204.

LYU Juan, GUO Weiyan, WANG Yuanji, LI Yamei, WANG Yingli, DUAN Shiwan. 115 cases of drug-related adverse reactions in the liver[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 200-204.

参考文献

[1] SHEN T, LIU Y, SHANG J, et al.Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241.
[2] Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2015, 31(11): 1752-1769.
[3] HE Z, ZHAO Y, GUO C, et al.Prevalence and risk factors for esophageal squamous cell cancer and precursor lesions in Anyang, China: a population-based endoscopic survey[J]. Br J Cancer, 2010, 103(7): 1085-1088.
[4] GAO Y, FANG WJ, ZHANG YL.Retrospective study of 185 patients with drug-induced liver injury[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2019, 28(7): 439-444.
[5] CHEN XQ. New Pharmacology(新编药物学)[M]. Beijing: People’s Medical Publishing House, 2018.
[6] AMACHER DE.Female gender as a susceptibility factor for drug-induced liver injury[J]. Hum Exp Toxicol, 2013, 33(9): 928-939.
[7] ALHADDAD O, ELSABAAWY M, ABDELSAMEEA E, et al.Presentations, causes and outcomes of drug-induced liver injury in egypt[J]. Sci Rep, 2020, 10(1): 5124-5133.
[8] GREWAL P, AHMAD J.Severe liver injury due to herbal and dietary supplements and the role of liver transplantation[J]. World J Gastroenterol, 2019, 25(46): 6704-6712.
[9] BJÖRNSSON ES. Hepatotoxicity of statins and other lipid-lowering agents[J]. Liver Int, 2017, 37(2): 173-178.
[10] JING J, TESCHKE R.Traditional Chinese medicine and herb-induced liver injury: comparison with drug- induced liver injury[J]. J Clin Transl Hepatol, 2018, 6(1): 57-68.
[11] XU CS.Effect of small dose prednisone on orbital inflammatory pseudotumor and its effect on liver function[J]. Chinese Hepatology(肝脏), 2016, 21(10): 901-902.
[12] ADAMEC I, PAVLOVIĆ I, PAVIČIĆ T, et al. Toxic liver injury after high-dose methylprednisolone in people with multiple sclerosis[J]. Mult Scler Relat Disord, 2018(25): 43-45.
[13] BENESIC A, ROTTER I, DRAGOI D, et al.Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury[J]. Clinical Gastroenterology and Hepatology, 2018, 16(9): 1488-1494.
[14] CAI RN, XUE HL, REN XD.Pharmaceutical care for one patient with liver injury induced by glycocorticoids[C]. The 13th youth pharmaceutical research exchange meeting of Chinese Pharmaceutical Association, 2016.
[15] ZHENG J, ZHENG S, FENG Q, et al. Dietary capsaicin and its anti-obesity potency: from mechanism to clinical implications[J]. Biosci Rep, 2017, 37(3): BSR20170286.
[16] QIU YL, MA L, ZHU XL, et al.Severe liver injury caused by orlistat[J]. ADRJ(药物不良反应杂志), 2019, 21(3): 231-232.
[17] DOUGLAS IJ, LANGHAM J, BHASKARAN K, et al.Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink[J]. BMJ, 2013(346): f1936.
[18] U. S. FDA. FDA Drug Safety Communication: completed safety review of Xenical/Alli (orlistat) andsevere liver injury [EB/OL]. (2009-04-24) [2020-06-25]. https://www.fda.gov/drugs/postmarket-drug-safety- informat -ion-patients-and-providers/fda-drug-safety-communication-completed-safety-review-xenicalalli-orlistat-and-severe-liver-injury.
[19] European Medicines Agency. European Medicines Agency starts review of orlistat-containing medicines [EB/OL]. (2011-09-22) [2020-06-25]. https://www.ema.europa.eu/en/news/european-medicines- agency-start s-review-orlistat-containing-medicines.
[20] National Medical Products Administration. Adverse drug reaction information circular (issue 36) Alert to the risk of serious liver damage caused by orlistat[EB/OL]. (2011-03-04)[2020-06-25]. http://www.nmpa.gov.cn/ WS04/CL 2155/318852.html.
[21] JIA WP, GUO DH, TIAN XY, et al.Analysis of 1110 cases of drug-induced liver injury in 79 hospitals[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(8): 481-485.
[22] HU PF, XIE WF.Corticosteroid therapy in drug-induced liver injury: pros and cons[J]. J Dig Dis, 2019, 20(3): 122-126.